Former Senator Arlen Specter Has Died at 82
Former U.S. Senator from Pennsylvania Arlen Specter, a man who embodied the idea of a left-leaning Republican and even switched to the Democratic Party late in his career, has died, his family announced today. He was 82.
Specter had recently been diagnosed with non-Hodgkin's lymphoma. It was not his first cancer diagnosis; in 2004 he had been diagnosed with advanced-stage unfavorable Hodgkin's lymphoma (stage IVB) but recovered following standard therapy, which included ABVD combination chemotherapy.
Senator Specter served the state of Pennsylvania in the Senate from 1980 through 2011, the longest Senate tenure in the state's history. Most recently he was teaching at the University of Pennsylvania Law School.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
